Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Phosphonoacetic acid is a simple organophosphorus compound and a member of the phosphonic acids. It acts as an antiviral agent by specifically inhibiting DNA polymerase in viruses—most notably herpesviruses—while having minimal effect on normal cellular polymerases. This selectivity results in low cellular toxicity. The drug blocks viral DNA synthesis by binding to the virus-induced DNA polymerase and preventing the addition of deoxynucleosides to elongating nascent chains during polynucleotide synthesis. Phosphonoacetic acid has demonstrated efficacy against herpes simplex virus (HSV) replication in vitro and in animal models of skin and ocular infections[1][2][3][4][6]. Its primary use has been experimental; it is not approved for clinical use.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on phosphonoacetic acid.